Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 7/20 | 0.39 |
| ▸ | NOS2 | P35228 | 7/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | F12 | P00748 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491842 | 0.78 | NOS2 (0.42) | NOS3NOS2USP7NOS1LOXL2 | |
| SCHEMBL21856017 | 0.77 | NOS3 (0.41) | NOS3NOS2USP7NOS1LOXL2 | |
| SCHEMBL29506010 | 0.77 | NOS3 (0.41) | NOS3NOS2USP7NOS1LOXL2 | |
| SCHEMBL3945531 | 0.75 | NOTUM (0.39) | NOS3NOS2USP7NOS1LOXL2 | |
| SCHEMBL29506023 | 0.75 | NOS3 (0.39) | NOS3NOS2USP7NOS1LOXL2 | |
| SCHEMBL21856159 | 0.75 | NOS3 (0.39) | NOS3NOS2USP7NOS1LOXL2 | |
| SCHEMBL28272763 | 0.75 | CYP2A6 (0.32) | NOS3NOS2HCAR1PRKCI | |
| SCHEMBL31423975 | 0.72 | ADORA2A (0.39) | NOS3NOS2LOXL2LOXHTT | |
| SCHEMBL16051380 | 0.71 | — | — | |
| SCHEMBL31381593 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | NOS3 1553/4885NOS2 1645/4885HCAR1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.